GlobeNewsWire
05 Aug 2026, 23:45 UTC · 1h ago
UPDATE - LifeMD Reports Second Quarter 2026 Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
05 Aug 2026, 23:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
LifeMD expects to exit 2026 with an annualized revenue run rate of approximately $250 million and annualized adjusted EBITDA of $22 million. — Provides concrete, forward-looking growth targets and profitability benchmarks for investors to value the company.
+0.60Adjusted EBITDA for the second quarter finished below the company's previously provided guidance range. — Missing profitability targets typically triggers negative short-term sentiment regarding management's execution or cost control.
-0.40The share of new weight management patients selecting multi-month packages increased from 25% to 85% following a pricing change. — Significantly increases predictable recurring revenue and improves customer lifetime value (LTV).
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Gross margin expanded to approximately 89% due to lower fulfillment costs and scaling of the in-house pharmacy. — Demonstrates operational efficiency and the ability to capture more of the value chain via vertical integration.
+0.30The transition to branded GLP-1 medications has weighed on near-term profitability. — Indicates a margin squeeze due to the higher cost of branded pharmaceutical therapies compared to alternatives.
-0.20Which stocks this story touches
The company is mentioned as a collaborator in the launch of XYOSTED, which is listed as a priority for growth.
While adjusted EBITDA missed guidance, the company reported strong gross margins, a growing recurring revenue base, and a positive outlook for the second half of 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
44m ago
